Victoria Colliver-- May 6, 2014
Maya, a 1-year-old German shepherd, has been taking Benadryl for her itchy skin, but her chronic allergy-associated skin condition persisted.
So after a trip to a veterinary clinic that specializes in dermatology, Maya's owners, Emily and Dave Leslie of San Jose, enrolled their pet in a clinical trial for a potential new drug - a dog version of Allegra, a well-known allergy drug for humans.
The company developing the drug, Burlingame's Kindred Biosciences Inc., specializes in turning drugs that have already shown to be safe and effective in humans into therapies for dogs, cats and other companion animals, including horses.
They are part of an animal pharmaceutical industry that is growing, fueled largely by an increasing passion that owners feel for their pets. Veterinary medicines and vaccines are estimated to represent a global market of $22 billion within the approximately $100 billion animal health industry. The bulk of that is livestock, but the companion pet sector is taking a bigger bite out of that market.
continue to read here
No comments:
Post a Comment